Tanja Fehm
Overview
Explore the profile of Tanja Fehm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
359
Citations
10731
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marthesheimer S, Hagenbeck C, Helbig M, Balan P, Fehm T, Schaal N
BMC Pregnancy Childbirth
. 2025 Feb;
25(1):216.
PMID: 40016647
Background: A satisfying birth experience has positive effects on the well-being of mother and child. The birth experience depends on subjective expectations and objective birth parameters, and the view of...
2.
On J, Ghaderi S, Rittmann C, Hoffmann G, Gier F, Woloschin V, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39940844
Triple-negative breast cancer (TNBC) represents the most aggressive breast carcinoma subtype lacking efficient therapeutic options. A promising approach in cancer treatment is the pharmacological inhibition of murine double minute 2...
3.
Pruss M, Cieslik J, Torok J, Dobrowolski J, Neubacher M, Helbig M, et al.
Arch Gynecol Obstet
. 2025 Feb;
PMID: 39912929
Background: Sonographically guided core needle biopsy (CNB) is a well-established tool for diagnosing breast lesions. Preoperative estrogen receptor (ER), progesterone receptor (PR), and HER2-receptor status are essential for a personalized...
4.
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401360.
PMID: 39883887
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer...
5.
Villacampa G, Llop-Guevara A, Filmann N, Herencia A, Herencia-Ropero A, Fasching P, et al.
Clin Cancer Res
. 2025 Jan;
31(5):808-814.
PMID: 39786436
Purpose: The randomized GeparOLA trial reported comparable pathologic complete response (pCR) rates with neoadjuvant treatment containing olaparib versus carboplatin. In this study, we evaluate the association between functional homologous recombination...
6.
Tegeler C, Hartkopf A, Banys-Paluchowski M, Krawczyk N, Fehm T, Jaeger B
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682108
The progress that has been made in recent years in relation to liquid biopsies in general and circulating tumor DNA (ctDNA) in particular can be seen as groundbreaking for the...
7.
Neubacher M, Darici D, Krawczyk N, Arslan M, Pruss M, Fehm T, et al.
Geburtshilfe Frauenheilkd
. 2024 Dec;
84(12):1135-1142.
PMID: 39649124
Introduction: Minimally invasive surgery is increasing in all fields of surgery. It is currently unknown whether structured training is superior to self-directed training. The aim of this study is to...
8.
Denkert C, Schneeweiss A, Rey J, Karn T, Hattesohl A, Weber K, et al.
Cell Rep Med
. 2024 Nov;
5(11):101825.
PMID: 39566464
Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059),...
9.
Rivandi M, Franken A, Yang L, Abramova A, Stamm N, Eberhardt J, et al.
J Transl Med
. 2024 Sep;
22(1):848.
PMID: 39304879
Background: Traditional genomic profiling and mutation analysis of single cells like Circulating Tumor Cells (CTCs) fails to capture post-translational and functional alterations of proteins, often leading to limited treatment efficacy....
10.
Voss F, Nienhaus F, Pietrucha S, Ruckhaberle E, Fehm T, Melz T, et al.
Cardiooncology
. 2024 Jul;
10(1):43.
PMID: 39014463
Aims: Cancer therapy-related cardiac dysfunction (CTRCD) is a dreaded complication of anthracycline therapy. CTRCD most frequently appears in patients with cardiovascular risk factors (CVR) or known cardiovascular disease. However, limited...